{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:37:27Z","timestamp":1783535847733,"version":"3.55.0"},"reference-count":68,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Children with CML need TKI treatment for many years, and the lack of knowledge about immune dysfunction with TKI has hindered routine immunizations. This review attempts to provide an overview of the effects of TKIs licensed for children (e.g., imatinib, dasatinib, and nilotinib) on immune function, as well as its implications on immunizations. We discuss surveillance strategies (e.g., immunoglobulin blood serum levels and hepatitis B reactivation) and immunizations. All inactivated vaccines (e.g., influenza, pneumococcal, and streptococcal) can be given during the treatment of CML in the chronic phase, although their efficacy may be lower. As shown in single cases of children and adults with CML, live vaccines (e.g., varicella, measles, mumps, rubella, and yellow fever) may be administered under defined circumstances with great precautions. We also highlight important aspects of COVID-19 in this patient population (e.g., the outcome of COVID-19 infection in adults with CML and in children with varying hemato-oncological diseases) and discuss the highly dynamic field of presently available different vaccination options. In conclusion, TKI treatment for CML causes humoral and cellular immune dysfunction, which is mild in most patients, and thus infectious complications are rare. Routine immunizations are important for health maintenance of children, but vaccinations for children with CML on TKI therapy should be carefully considered.<\/jats:p>","DOI":"10.3390\/jcm10184056","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T10:12:03Z","timestamp":1631095923000},"page":"4056","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-8838","authenticated-orcid":false,"given":"Meinolf","family":"Suttorp","sequence":"first","affiliation":[{"name":"Hematology and Oncology, Medical Faculty, Technical University, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Webster Carrion","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2021, September 07). Cancer Statistics, Table 3.1: Age-Adjusted Incidence Rates and Number of Cases By Period of Diagnosis for Major Cancer Sites and Subsites, Available online: https:\/\/seer.cancer.gov\/statistics\/nccr\/details.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399403006835","article-title":"Molecular pathogenesis of chronic myeloid leukaemia","volume":"5","author":"Smith","year":"2003","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/156800907780618293","article-title":"The kinase inhibitor imatinib\u2014An immunosuppressive drug?","volume":"7","author":"Wolf","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","article-title":"Effects of imatinib on normal hematopoiesis and immune activation","volume":"23","author":"Appel","year":"2005","journal-title":"Stem Cells"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e27368","DOI":"10.1002\/pbc.27368","article-title":"Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia\/Lymphoma Study Group","volume":"65","author":"Kurosawa","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity against Cancer and Viral Infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00432-017-2378-6","article-title":"Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia","volume":"143","author":"Rajala","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"Khoder","year":"2013","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/08880018.2020.1759739","article-title":"Imatinib-Induced Hypogammaglobulinemia in Children and Adolescents with Chronic Myeloid Leukemia","volume":"37","author":"Totadri","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.idc.2020.02.008","article-title":"Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies","volume":"34","author":"Kin","year":"2020","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Intracellular signaling pathways: Tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3748\/wjg.v20.i22.6716","article-title":"Hepatitis C virus reactivation in cancer patients in the era of targeted therapies","volume":"20","author":"Yazici","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_19","first-page":"65","article-title":"Diseases at the crossroads: Chronic myelogenous leukemia and tuberculosis","volume":"18","author":"Bhatnagar","year":"2015","journal-title":"Arch. Iran Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17474086.2021.1875818","article-title":"Association of tuberculosis in patients with chronic myeloid leukemia: A treatment proposal based on literature review","volume":"14","author":"Iqbal","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2016.1260127","article-title":"Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia","volume":"58","author":"Orlandi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1073274820976594","DOI":"10.1177\/1073274820976594","article-title":"Evaluation of Hepatitis B Reactivation among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors","volume":"27","author":"Atteya","year":"2020","journal-title":"Cancer Control"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MOP.0000000000000846","article-title":"Advances in vaccinating immunocompromised children","volume":"32","author":"Miller","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: Guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2010.032664","article-title":"Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host","volume":"96","author":"Garland","year":"2011","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s005200050196","article-title":"Tetanus immunity in patients with hematological malignancies","volume":"6","author":"Hamarstrom","year":"1998","journal-title":"Support Care Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e28706","DOI":"10.1002\/pbc.28706","article-title":"Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry","volume":"68","author":"Millot","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5306\/wjco.v11.i6.308","article-title":"Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia","volume":"11","author":"Suttorp","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fimmu.2020.00628","article-title":"Vaccination with Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment","volume":"11","author":"Hildebrand","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"tax082","DOI":"10.1093\/jtm\/tax082","article-title":"Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics","volume":"25","author":"Huber","year":"2018","journal-title":"J. Travel Med."},{"key":"ref_32","first-page":"976","article-title":"Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate","volume":"9","author":"Mattiuzzi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000491546","article-title":"Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience","volume":"140","author":"Giona","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/381592","article-title":"The theory of measles elimination: Implications for the design of elimination strategies","volume":"189","author":"Gay","year":"2004","journal-title":"J. Infect Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.15585\/mmwr.mm6747a6","article-title":"Progress Toward Regional Measles Elimination\u2014Worldwide, 2000\u20132017","volume":"67","author":"Dabbagh","year":"2018","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMcp1905181","article-title":"Measles","volume":"381","author":"Strebel","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.15585\/mmwr.mm6945a6","article-title":"Progress Toward Regional Measles Elimination\u2014Worldwide, 2000\u20132019","volume":"69","author":"Patel","year":"2020","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_38","unstructured":"(2021, April 13). Worldwide Measles Deaths Climb 50% from 2016 to 2019 Claiming over 207 500 Lives in 2019. Available online: https:\/\/www.who.int\/news\/item\/12-11-2020-worldwide-measles-deaths-climb-50-from-2016-to-2019-claiming-over-207-500-lives-in-2019."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tanveer, M., Ahmed, A., Siddiqui, A., and Gudi, S.K. (2021). The mystery of plummeting cases of measles during COVID-19 pandemic in Pakistan: Hidden impact of collateral damage. J. Med. Virol.","DOI":"10.1002\/jmv.27045"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Poethko-Muller, C., and Mankertz, A. (2012). Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042867"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1016\/j.vaccine.2014.04.042","article-title":"Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer","volume":"32","author":"Bochennek","year":"2014","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm1265","article-title":"Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases","volume":"11","author":"Reeves","year":"2005","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JVI.01814-10","article-title":"Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases","volume":"85","author":"Reeves","year":"2011","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Klitting, R., Fischer, C., Drexler, J.F., Gould, E.A., Roiz, D., Paupy, C., and de Lamballerie, X. (2018). What Does the Future Hold for Yellow Fever Virus? (II). Genes, 9.","DOI":"10.20944\/preprints201807.0378.v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/jtm.12173","article-title":"No booster dose for yellow fever vaccination: What are the consequences for the activity of vaccination in travel clinics?","volume":"22","author":"Wyplosz","year":"2015","journal-title":"J. Travel Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-6143.2004.00708.x","article-title":"Prevention of infection in adult travelers after solid organ transplantation","volume":"5","author":"Kotton","year":"2005","journal-title":"Am. J. Transplant"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children","volume":"10","author":"Reis","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.vaccine.2019.12.042","article-title":"Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals","volume":"38","author":"Burkhard","year":"2020","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-3062.2011.00686.x","article-title":"Yellow fever vaccination in organ transplanted patients: Is it safe? A multicenter study","volume":"14","author":"Azevedo","year":"2012","journal-title":"Transpl. Infect Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1590\/s1678-9946202163013","article-title":"Adverse events following yellow fever vaccination in immunocompromised persons","volume":"63","author":"Lara","year":"2021","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/s41375-020-0904-z","article-title":"Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey","volume":"34","author":"Breccia","year":"2020","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/bjh.16758","article-title":"Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: A Campus ALL study","volume":"190","author":"Foa","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1038\/s41388-020-01495-6","article-title":"SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia","volume":"39","author":"Chu","year":"2020","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Coleman, C.M., Sisk, J.M., Halasz, G., Zhong, J., Beck, S.E., Matthews, K.L., Venkataraman, T., Rajagopalan, S., Kyratsous, C.A., and Frieman, M.B. (2017). CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome. J. Virol., 91.","DOI":"10.1128\/JVI.01825-16"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/CMR.14.1.98-113.2001","article-title":"Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans","volume":"14","author":"Bendinelli","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cmi.2020.01.011","article-title":"Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors","volume":"26","author":"Focosi","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fonc.2020.01428","article-title":"Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2","volume":"10","author":"Galimberti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_59","unstructured":"(2021, September 02). COUNTER-COVID\u2014Oral Imatinib to Prevent Pulmonary Vascular Leak in Covid19\u2014A Randomized, Double\u2014Blind, Placebo Controlled, Clinical Trial in Patients with Severe Covid19 Disease\u2019. Effecten van Imatinib bij Pati\u00ebnten met Longschade Door COVID-19 Infectie. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001236-10\/NL."},{"key":"ref_60","unstructured":"(2021, September 02). Imatinib in COVID-19 Disease in Aged Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04357613."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-020-0853-6","article-title":"COVID-19 in persons with chronic myeloid leukaemia","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140161","article-title":"COVID-19 in patients (pts) with Chronic Myeloid Leukemia (CML): Results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study","volume":"136","author":"Rea","year":"2020","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/s41375-020-0964-0","article-title":"Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study","volume":"34","author":"Ector","year":"2020","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2007617","article-title":"Children with Covid-19 in Pediatric Emergency Departments in Italy","volume":"383","author":"Parri","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e29005","DOI":"10.1002\/pbc.29005","article-title":"Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review","volume":"68","author":"Meena","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 Vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.17402","article-title":"Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"193","author":"Harrington","year":"2021","journal-title":"Br. J. Haematol"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Harrington, P., Doores, K.J., Radia, D., O\u2019Reilly, A., Lam, H.P.J., Seow, J., Graham, C., Lechmere, T., McLornan, D., and Dillon, R. (2021). Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br. J. Haematol.","DOI":"10.1111\/bjh.17568"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:58:39Z","timestamp":1760165919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":68,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10184056"],"URL":"https:\/\/doi.org\/10.3390\/jcm10184056","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}